Hi, what are you looking for?
Jewish Business News
Search results for " Erez Vigodman"
Business
Bloomberg reports Mylan chairman Robert Coury as telling investors he is prepared to reduce Perrigo shareholders' risk
Business
Teva declined the chance because it does not operate in the store-brand OTC market, Perrigo's main activity.
Business
Reuters Exclusive: Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to...
Leadership & A-List
The Teva shareholder and digital printing pioneer thinks Teva should be investing in innovation, not cheap commodity drugs.
Business
Mylan's filing on executive compensation reveals much higher pay than at Teva.
Business
Board concludes that approach grossly undervalues Mylan, includes Teva stock, and would expose Mylan to a problematic culture and leadership with poor record of...
Business
Bloomberg reports that Teva is working with Barclays Bank on a takeover bid for Mylan.
Business
"Reuters" said the settlement would be the largest ever paid over allegations of delaying generic drugs.
Business
Teva’s American Depositary Receipts rose 2.2 percent to $63.31, giving it a market value of just under $54 billion.
Business
Teva is selling four targeted oncology development programs to Ignyta for 6% of the biotech company.